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VIEWS AND REVIEWS
Epileptologists probe vagus nerve stimulation 
in children with refractory epilepsy: a promise 
against sudden unexpected death in epilepsy
Epileptologistas indicam a estimulação do nervo vago em crianças com epilepsia 
refratária: uma promessa contra a morte súbita em epilepsia
Vera C. Terra1, Meire A. Nisyiama1, João Abrão2, Américo C. Sakamoto1, Helio R. Machado1, Ricardo M. Arida3, 
Esper A. Cavalheiro4, Fulvio Alexandre Scorza4
Worldwide, epilepsy is considered the most common seri-
ous neurological condition that knows no geographic, social, 
or racial boundaries, occurring in men and women and af-
fecting people of all ages, though it affects more frequently 
young people in the first two decades of life and those over 
the age of 601,2. In a more specific way, a major proportion of 
people with epilepsy falls in the pediatric group (18 years-old 
or less), and approximately 25% of those patients have medi-
cally intractable epilepsy3. Furthermore, only 10 to 20% of the 
children with epilepsy, who remain presenting active epilep-
sy in adulthood, will have spontaneous seizure remission, 
suggesting that early attempts to control epilepsy should be 
pursuit4-6. Often, epilepsy is still seen as a benign condition in 
which individuals only have seizures. Unfortunately, the story 
is not as simple as it seems. Epilepsy is a malignant condition 
that has a high rate of premature death compared with the 
general population7-9.
Most of the excess death is due to the underlying dis-
ease causing epilepsy, however some is epilepsy-related, 
including trauma, suicide, aspiration pneumonia, status 
epilepticus, mostly due to sudden unexpected death in ep-
ilepsy (SUDEP), which is a leading cause of mortality in 
people with epilepsy7-9. From an epidemiological stand-
point, results from a US population-based study indicate 
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ABSTRACT
It is clear that sudden unexpected death in epilepsy (SUDEP) is mainly a problem for people with refractory epilepsy, but our understanding 
of the best way to its prevention is still incomplete. Although the pharmacological treatments available for epilepsies have expanded, some 
antiepileptic drugs are still limited in clinical efficacy. In the present paper, we described an experience with vagus nerve stimulation (VNS) 
treatment by opening space and providing the opportunity to implement effective preventative maps to reduce the incidence of SUDEP in 
children and adolescents with refractory epilepsy.
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RESUMO
Está claro que a morte súbita e inesperada em epilepsias (SUDEP) é principalmente um problema para as pessoas com epilepsia refratária, 
mas o entendimento para estabelecer medidas preventivas ainda está incompleto. Embora os tratamentos farmacológicos disponíveis para 
epilepsias tenham sido expandidos, algumas drogas antiepilépticas ainda são limitadas em termos de eficácia clínica. No presente trabalho, 
foi descrita uma experiência com a estimulação do nervo vago (VNS), abrindo espaço e fornecendo a oportunidade de implementar eficazes 
mapas preventivoss para reduzir a incidência da SUDEP em crianças e adolescentes com epilepsia refratária.
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that the risk of sudden death in people with epilepsy is 
estimated to be at least 20 times higher than that of the 
general population10. In general terms, SUDEP is respon-
sible for 7.5 to 17% of all deaths in people with epilepsy, 
and it has an incidence among adults between 1:500 and 
1:1,000 patient-years11. Concerning risk factors, the main 
currently described are refractoriness of the epileptic con-
dition, presence of convulsive seizures, early onset of ep-
ilepsy, antiepileptic medication (polytherapy with anti-
epileptic drugs), young age, and duration of the seizure 
disorder9,12,13. The causes of SUDEP are still unknown, but 
researches consistently suggest that the main mechanism 
for SUDEP is autonomic dysregulation, i.e., cardiac and re-
spiratory abnormalities during and after seizures9,12-14. In 
addition, it is clear that SUDEP is mainly, but not exclu-
sively, a problem for people with uncontrolled epilepsy13, 
but our understanding of the best way to its prevention is 
still incomplete. Strict evidence still lacks for its effective-
ness, but epidemiologic and observational data seem to 
suggest some measures to minimize the risk of SUDEP, and 
these include: good seizure control, stress reduction, par-
ticipation in physical activity and sports (with appropriate 
professional supervision), dietary management (omega-3 
supplementation), night supervision, family members’ 
knowledge of cardiopulmonary resuscitation techniques, 
and the basics of defibrillator use13,15,16.
Despite the great scientific advances of SUDEP over the 
past two decades, most of the information described above 
was conducted in adults and, unfortunately, we still have lit-
tle data regarding SUDEP in children17,18. According to the 
excellent review article published recently by Sascha Meyer 
et al.18, epileptic children and adolescents with refractory sei-
zures, early-onset epilepsy, and developmental retardation 
seem to be at higher risk for SUDEP. Following this line of rea-
soning, we reviewed the occurrence of SUDEP in children in 
our epilepsy unit over an eight-year period19. Our study evalu-
ated SUDEP incidence in a cohort of children aged between 0 
and 18 years-old, who were evaluated in the Clinical Hospital 
of Ribeirão Preto in 2000 and followed-up until June, in 2008. 
Briefly, from the 835 patients evaluated, 12 had suffered 
SUDEP and nearly all of the SUDEP cases in our children 
were related to chronic uncontrolled epilepsy (daily – 50.0%, 
two to four/weeks – 41.7%, monthly – 8.3%). Furthermore, 
the high frequency of generalized tonic-clonic seizures and 
polytherapy with antiepileptic drugs may also be highlighted 
as risk factors in our study19.
By assessing the information set out so far and consid-
ering that although the availability of pharmacological and 
surgical treatment for epilepsy has expanded, antiepileptic 
drugs and some resective procedures are still limited in clin-
ic efficacy. Thus, the desire to find alternative treatments for 
untreatable epilepsy has led epileptologists to use therapeu-
tic devices in order to minimize the occurrence of SUDEP. For 
that, vagus nerve stimulation (VNS) may receive a prominent 
role in this scenario. It has been established that patients 
with medically intractable epilepsy, who are not candidates 
for epilepsy surgery, could benefit from neurostimulation20. 
Hence, VNS therapy is the only neurostimulation modal-
ity approved by the Food and Drug Administration (FDA). It 
has been shown to be efficacious and as well tolerated in chil-
dren and adolescents as in adults20. Furthermore, it has been 
shown to be a cost-effective treatment, reducing direct med-
ical costs, and improving health-related quality of life mea-
sures20. In a similar way, we have the same positive experi-
ence with VNS therapy. 
In brief, we analyzed 36 patients up to 18 years-old, 
with medically intractable epilepsy submitted to VNS im-
plantation. In these patients, a reduction of at least 50% of 
seizures was achieved in 61.3% of the cases and 12.1% 
of the individuals had more than 90% of seizure frequency 
reduction. Furthermore, 47.2% of the patients needed fre-
quently hospitalization before VNS implantation and, in 
follow-up, this number dropped out to 8.3%. In sum, we 
concluded that VNS demonstrated to be effective in re-
ducing seizure frequency and reducing the need of hos-
pitalization in children with some refractory epilepsies, 
and it should be considered as an option even in countries 
with limited resources. 
On the whole, it seems reasonable to assume that the 
risk of sudden death is clearly increased in the epilepsy 
population, and SUDEP is the most important direct epi-
lepsy-related cause of death. The establishment of SUDEP 
mechanisms is important for starting preventative mea-
sures for SUDEP and for striving to the best control of sei-
zures. Finally, these VNS results open space and provide 
us the opportunity of implementing effective preventative 
maps to reduce SUDEP incidence in children and adoles-
cents with refractory epilepsy.
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